Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126658) titled 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Dose-Finding Clinical Study of HZ-A-018 in the Treatment of Adult Chronic Spontaneous Urticaria' on June 12.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First People's Hospital of Hangzhou
Condition:
Urticaria
Intervention:
Group A:HZ-A-018 50 mg tablet, once daily, orally for 12 consecutive weeks.
Group B:HZ-A-018 75 mg tablet, once daily, orally for 12 consecutive weeks.
Group C:HZ-A-018 100 mg tablet, once daily, orally for 12 consecutive weeks.
Recruitment Status: Recruiting
Phase: 2
Date of First...